Immunic CSO Discusses Breaking the IBD Stigma to Mark Crohn's and Colitis Awareness Week | NASDAQ:IMUX

Proactive Investors04:15 ET

B.Riley Financial Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $6

Moomoo NewsNov 26 01:32 ET · Ratings

Immunic's Promising Pipeline Progress and Stable Financials Justify Buy Rating

TipRanksNov 26 01:05 ET · Ratings

Immunic, Inc. to Participate in Investor Conference in December

ImmunicNov 26 00:00 ET

Immunic Price Target Announced at $10.00/Share by HC Wainwright & Co.

Dow JonesNov 25 08:35 ET · Ratings

Express News | Immunic, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating

ReutersNov 25 06:02 ET